How long do you usually take osimertinib?

As a targeted therapy, Osimertinib is mainly used to treat patients with EGFR-mutated non-small cell lung cancer (NSCLC). It is a third-generation EGFR tyrosine kinase inhibitor (TKI) that prevents the growth and spread of cancer cells by specifically inhibiting the activity of EGFR mutant receptors. The duration of osimertinib use generally depends on the patient's specific condition, response to treatment, and drug tolerance.

In clinical applications, treatment with osimertinib usually continues until the patient's disease progresses or adverse drug reactions occur. For patients who initially take osimertinib, if the disease is well controlled and the patient does not experience significant side effects, they can continue to take it for months or even years. The duration of treatment is usually closely related to the patient's response to the drug, and treatment may be continued if the patient's condition is stably controlled and no significant side effects occur.

However, some patients may develop drug resistance, often after months or years of drug use. Drug resistance may be related to changes in EGFR gene mutations, especially in the case of T790M mutations, which may lead to a weakening of the effect of osimertinib. In this case, the doctor will decide whether the treatment plan needs to be adjusted based on the patient's condition and further genetic testing results, and may choose other drugs or treatments.

In most cases, treatment with osimertinib should be tailored by a physician based on the patient's specific response and tolerability. Patients should undergo regular imaging examinations and related biomarker testing during use to evaluate the effect of treatment and decide whether to continue taking it.

Reference materials:https://go.drugbank.com/drugs/DB09330